BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 8107781)

  • 1. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1.
    Acharya KR; Passalacqua EF; Jones EY; Harlos K; Stuart DI; Brehm RD; Tranter HS
    Nature; 1994 Jan; 367(6458):94-7. PubMed ID: 8107781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 A resolution: implications for superantigen recognition by MHC class II molecules and T-cell receptors.
    Papageorgiou AC; Tranter HS; Acharya KR
    J Mol Biol; 1998 Mar; 277(1):61-79. PubMed ID: 9514739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The crystal structure of staphylococcal enterotoxin H: implications for binding properties to MHC class II and TcR molecules.
    Hâkansson M; Petersson K; Nilsson H; Forsberg G; Björk P; Antonsson P; Svensson LA
    J Mol Biol; 2000 Sep; 302(3):527-37. PubMed ID: 10986116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxy-terminal residues of major histocompatibility complex class II-associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells.
    Wen R; Broussard DR; Surman S; Hogg TL; Blackman MA; Woodland DL
    Eur J Immunol; 1997 Mar; 27(3):772-81. PubMed ID: 9079821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1.
    Buonpane RA; Moza B; Sundberg EJ; Kranz DM
    J Mol Biol; 2005 Oct; 353(2):308-21. PubMed ID: 16171815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
    Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM
    Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes.
    Arcus VL; Proft T; Sigrell JA; Baker HM; Fraser JD; Baker EN
    J Mol Biol; 2000 May; 299(1):157-68. PubMed ID: 10860729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification from a phage display library of peptides that bind to toxic shock syndrome toxin-1 and that inhibit its binding to major histocompatibility complex (MHC) class II molecules.
    Sato A; Ida N; Fukuyama M; Miwa K; Kazami J; Nakamura H
    Biochemistry; 1996 Aug; 35(32):10441-7. PubMed ID: 8756700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of a T-cell receptor beta-chain complexed with a superantigen.
    Fields BA; Malchiodi EL; Li H; Ysern X; Stauffacher CV; Schlievert PM; Karjalainen K; Mariuzza RA
    Nature; 1996 Nov; 384(6605):188-92. PubMed ID: 8906797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superantigen natural affinity maturation revealed by the crystal structure of staphylococcal enterotoxin G and its binding to T-cell receptor Vbeta8.2.
    Fernández MM; Bhattacharya S; De Marzi MC; Brown PH; Kerzic M; Schuck P; Mariuzza RA; Malchiodi EL
    Proteins; 2007 Jul; 68(1):389-402. PubMed ID: 17427250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
    von Bonin A; Ehrlich S; Malcherek G; Fleischer B
    Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1.
    Karp DR; Teletski CL; Scholl P; Geha R; Long EO
    Nature; 1990 Aug; 346(6283):474-6. PubMed ID: 2377209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality.
    Kum WW; Laupland KB; Chow AW
    Can J Microbiol; 2000 Feb; 46(2):171-9. PubMed ID: 10721486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of receptor mimics that inhibit superantigen pathogenesis.
    Möllhoff M; Zanden HB; Shiflett PR; Gupta G
    J Mol Recognit; 2005; 18(1):73-83. PubMed ID: 15459942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro.
    Seth A; Stern LJ; Ottenhoff TH; Engel I; Owen MJ; Lamb JR; Klausner RD; Wiley DC
    Nature; 1994 May; 369(6478):324-7. PubMed ID: 8183371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen.
    Jardetzky TS; Brown JH; Gorga JC; Stern LJ; Urban RG; Chi YI; Stauffacher C; Strominger JL; Wiley DC
    Nature; 1994 Apr; 368(6473):711-8. PubMed ID: 8152483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury.
    Brogan PA; Shah V; Klein N; Dillon MJ
    Arthritis Rheum; 2004 Feb; 50(2):589-97. PubMed ID: 14872503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural dichotomy of staphylococcal enterotoxin C superantigens leading to MHC class II-independent activation of T lymphocytes.
    Lamphear JG; Bohach GA; Rich RR
    J Immunol; 1998 Mar; 160(5):2107-14. PubMed ID: 9498747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel HLA class II-independent TCR-mediated T cell activation mechanism is distinguished by the V beta specificity of the proliferating oligoclones and their capacity to generate interleukin-2.
    Dennig D; Yan Y; Ferguson K; O'Reilly RJ
    Cell Immunol; 1996 Aug; 171(2):200-10. PubMed ID: 8806788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity.
    Newton DW; Dohlsten M; Olsson C; Segrén S; Lundin KE; Lando PA; Kalland T; Kotb M
    J Immunol; 1996 Nov; 157(9):3988-94. PubMed ID: 8892632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.